Bemotrizinol Sunscreen: U.S. Compliance Checklist for Foreign Manufacturers

If you manufacture sunscreens outside the United States and you're eyeing bemotrizinol, you're in the highest-stakes group of all — and the one with the most to gain. Foreign manufacturers shipping into the U.S. carry the full weight of OTC drug compliance, and getting it right is exactly what separates a smooth launch from a detained shipment. Here's the roadmap.

First, the timeline

Bemotrizinol was finalized June 9, 2026 and is effective August 9, 2026 — but the ~18-month exclusivity on the original data means broad third-party entry realistically opens around late 2027, unless you license the ingredient or submit your own data. Treat the time between now and then as your build window.

The compliance checklist

In the U.S., sunscreens are regulated as OTC drugs. Before product can be legally distributed, a foreign manufacturer generally needs each of the following in place:

• Establishment registration. Every facility that manufactures, packages, or labels the drug must register with the FDA and renew annually.

• Drug listing (NDC + SPL). Obtain a labeler code and National Drug Code, then submit electronic product listing in Structured Product Labeling format.

• A compliant Drug Facts panel. Active ingredient, purpose, uses, warnings, and directions in the exact U.S. OTC format.

• Final-formulation testing. SPF and broad-spectrum testing per monograph methods, supporting every claim on the label.

• OTC cGMP. Manufacture under current Good Manufacturing Practice for drugs, with batch and quality records.

• A U.S. Agent. A U.S.-based point of contact to receive and relay FDA communications and inspection notices.

• Adverse event reporting. A process to receive reports and submit serious adverse events to the FDA, generally within 15 business days.

Where foreign manufacturers get tripped up

Three failure points recur: a home-market label that was never reformatted into Drug Facts; missing or mismatched testing behind the SPF and broad-spectrum claims; and no U.S. Agent on file, which stalls registration. Each is avoidable with a checklist and a plan.

Build the file now

Because of the exclusivity window, you have a rare luxury: time to prepare before you can broadly launch. Use it. Confirm your pathway, reformat your label, commission testing, appoint your U.S. Agent, and assemble your registration and listing package so you're ready the day the market opens.

Get the checklist

Our one-page Bemotrizinol (BEMT) U.S. Market-Entry Compliance Checklist maps every step above. Download the free checklist → Or let Axentra run the whole pathway for you with the U.S. Market Entry Package — including U.S. Agent service.

---

Frequently asked questions

Do foreign sunscreen manufacturers really need to register with the FDA?

Yes. Any establishment that manufactures or processes an OTC drug for the U.S. market must register, and a foreign establishment must also designate a U.S. Agent.

Can I use my existing SPF test results from my home market?

Generally no. The monograph specifies test methods, and claims must be supported by testing on your final formulation under those methods.

How long does registration and listing take?

It varies, but the work — appointing a U.S. Agent, registering establishments, securing a labeler code, and preparing SPL — is best started well ahead of your intended launch.